CTIS.eu › Cities › France › Paris
Paris
France
2,286 total trials
1,022 recruiting
Filter these 2,286 trials by phase, condition, sponsor and more.
Open in Search →
2023-507970-42-00
5
2021-03-31
PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
2023-506962-30-00
5
2021-03-29
Non-alcoholic steatohepatitis (NASH)
2024-512028-12-00
4
2021-03-19
Advanced ROS1-positive non-small cell lung cancer
2024-517816-31-00
4
2021-03-19
For patients with advanced/metastatic gastric adenocarcinomas in
progr
2022-502600-79-00
4
2021-03-16
Endometrial cancer
2023-505835-11-00
5
2021-03-12
Chronic Migraine
2023-505964-13-00
5
2021-03-09
Hemophilia A
2022-502705-15-00
5
2021-03-08
High-risk muscle-invasive bladder cancer
2023-507184-19-00
5
2021-02-22
Juvenile Psoriatic Arthritis
Enthesitis Related Arthritis
2023-507890-17-00
5
2021-02-22
Anemia associated with myeloproliferative neoplasm (MPN)-associated my
2022-503073-11-00
5
2021-02-13
Stage IIIb cardiac AL amyloidosis
2024-513659-34-00
9
2021-02-12
Relapsed/Refractory aggressive B-NHL
2024-512238-13-00
4
2021-02-10
Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer
2024-515149-41-00
1
2021-02-04
Advanced Hematologic Malignancies
2024-513325-23-00
4
2021-02-03
Myelofibrosis
2023-507338-26-00
5
2021-02-01
Histologically documented gastric or gastroesophageal junction adenoca
2024-513252-15-00
4
2021-01-28
IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
2024-515944-22-00
4
2021-01-19
BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
2024-512232-30-00
10
2021-01-18
Primary Biliary Cholangitis
2024-514502-31-00
5
2021-01-11
Prurigo Nodularis
2023-504830-23-00
5
2020-12-16
B-cell Lymphoma
2024-510714-32-00
4
2020-12-10
Patiens with locally advanced/metastatic endometrial carcinoma or cerv
2023-504959-27-00
5
2020-12-09
Participants with Limited Stage-Small Cell Lung Cancer, who have recei
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
Showing 1,657–1,680 of 2,286 trials